Dec 29, 2021 11:15am EST Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
Dec 08, 2021 7:30am EST Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Nov 10, 2021 9:00am EST Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
Nov 01, 2021 9:00am EDT Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
Sep 16, 2021 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Emerging as Leader in Pursuit of More-Effective Hypertension Treatment
